These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
319 related items for PubMed ID: 21951990
1. Improving treatment adherence in patients with schizophrenia. Kane JM. J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990 [Abstract] [Full Text] [Related]
2. Treatment adherence in schizophrenia and schizoaffective disorder. Goff DC, Hill M, Freudenreich O. J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119 [Abstract] [Full Text] [Related]
3. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. Kane JM. J Clin Psychiatry; 2006 Apr; 67 Suppl 5():9-14. PubMed ID: 16822091 [Abstract] [Full Text] [Related]
4. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Agid O, Foussias G, Remington G. Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707 [Abstract] [Full Text] [Related]
5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343 [Abstract] [Full Text] [Related]
7. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. Morrissette DA, Stahl SM. CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201 [Abstract] [Full Text] [Related]
8. Substance abuse and the management of medication nonadherence in schizophrenia. Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M. J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865 [Abstract] [Full Text] [Related]
10. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry]. Stompe T, Schanda H. Neuropsychiatr; 2011 Jun; 25(2):75-84. PubMed ID: 21672506 [Abstract] [Full Text] [Related]
12. Assessment of clinician awareness of nonadherence using a new structured rating scale. Clayton CD, Veach J, Macfadden W, Haskins J, Docherty JP, Lindenmayer JP. J Psychiatr Pract; 2010 May; 16(3):164-9. PubMed ID: 20485104 [Abstract] [Full Text] [Related]
13. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. Citrome L. CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847 [Abstract] [Full Text] [Related]
16. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane JM. J Clin Psychiatry; 2003 Nov; 64 Suppl 16():34-40. PubMed ID: 14680417 [Abstract] [Full Text] [Related]
18. Relapse and rehospitalization: comparing oral and depot antipsychotics. Schooler NR. J Clin Psychiatry; 2003 Nov; 64 Suppl 16():14-7. PubMed ID: 14680414 [Abstract] [Full Text] [Related]
19. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Sun SX, Liu GG, Christensen DB, Fu AZ. Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454 [Abstract] [Full Text] [Related]